Allspring Global Investments Holdings LLC Has $275.48 Million Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Allspring Global Investments Holdings LLC cut its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 2.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,165,306 shares of the medical research company's stock after selling 29,920 shares during the quarter. Allspring Global Investments Holdings LLC owned 2.27% of Charles River Laboratories International worth $275,478,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. VisionPoint Advisory Group LLC raised its stake in shares of Charles River Laboratories International by 105.7% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company's stock worth $28,000 after purchasing an additional 74 shares in the last quarter. Headlands Technologies LLC purchased a new stake in shares of Charles River Laboratories International during the 3rd quarter worth about $37,000. Operose Advisors LLC purchased a new stake in shares of Charles River Laboratories International during the 3rd quarter worth about $42,000. Covestor Ltd raised its stake in shares of Charles River Laboratories International by 100.0% during the 1st quarter. Covestor Ltd now owns 174 shares of the medical research company's stock worth $49,000 after purchasing an additional 87 shares in the last quarter. Finally, Venturi Wealth Management LLC raised its stake in shares of Charles River Laboratories International by 74.7% during the 3rd quarter. Venturi Wealth Management LLC now owns 262 shares of the medical research company's stock worth $51,000 after purchasing an additional 112 shares in the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Stock Performance

Shares of NYSE:CRL traded up $1.80 during trading on Monday, hitting $254.90. 442,617 shares of the stock were exchanged, compared to its average volume of 563,569. Charles River Laboratories International, Inc. has a 1-year low of $161.65 and a 1-year high of $275.00. The company has a market capitalization of $13.13 billion, a price-to-earnings ratio of 27.48, a price-to-earnings-growth ratio of 1.98 and a beta of 1.40. The company's fifty day simple moving average is $249.73 and its 200-day simple moving average is $218.46. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.16 and a current ratio of 1.52.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.39 by $0.07. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $991.25 million. During the same quarter last year, the firm earned $2.98 EPS. Charles River Laboratories International's revenue for the quarter was down 7.9% compared to the same quarter last year. Sell-side analysts expect that Charles River Laboratories International, Inc. will post 11.01 EPS for the current fiscal year.

Insider Activity at Charles River Laboratories International

In related news, EVP Shannon M. Parisotto sold 5,882 shares of the business's stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total value of $1,418,738.40. Following the sale, the executive vice president now owns 2,596 shares of the company's stock, valued at approximately $626,155.20. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, EVP Shannon M. Parisotto sold 5,882 shares of the business's stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total value of $1,418,738.40. Following the sale, the executive vice president now owns 2,596 shares of the company's stock, valued at approximately $626,155.20. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP William D. Barbo sold 4,050 shares of the business's stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total value of $1,006,425.00. Following the completion of the sale, the vice president now directly owns 22,879 shares in the company, valued at approximately $5,685,431.50. The disclosure for this sale can be found here. Insiders have sold a total of 14,932 shares of company stock valued at $3,693,663 in the last 90 days. 1.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on CRL. TheStreet raised Charles River Laboratories International from a "c+" rating to a "b-" rating in a research note on Friday, March 1st. Robert W. Baird raised their price objective on Charles River Laboratories International from $252.00 to $268.00 and gave the company an "outperform" rating in a research note on Thursday, February 15th. Evercore ISI raised their price objective on Charles River Laboratories International from $260.00 to $265.00 and gave the company an "outperform" rating in a research note on Thursday, February 15th. JPMorgan Chase & Co. raised their price objective on Charles River Laboratories International from $270.00 to $280.00 and gave the company an "overweight" rating in a research note on Thursday, February 15th. Finally, UBS Group raised their price objective on Charles River Laboratories International from $270.00 to $290.00 and gave the company a "buy" rating in a research note on Thursday, February 15th. Five analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, Charles River Laboratories International currently has an average rating of "Moderate Buy" and a consensus price target of $253.23.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.